Mydriasis is the medical term for an unusual dilation or widening of the pupils. There are various causes of this fixed dilation of the pupils. Normally, a person’s pupils dilate when the light is dim ...

Pupils are the black circles in your eyes. They gather light and bring it to the retina to form images. Typically, the pupils dilate, or widen, in response to low light so they can collect more light.

Please provide your email address to receive an email when new articles are posted on . Three years ago, tragedy struck my family with the loss of my brother due to metastatic lung cancer. My brother ...

You look in the mirror and notice that the dark circles in the middle of your eyes are bigger than usual. What's going on? Those dark circles are your pupils, the openings that let light enter your ...

This page lists all known medications that could potentially lead to 'Mydriasis' as a side effect. It's important to note that mild side effects are quite common with medications. The medication(s) ...

Credit: Shutterstock. Ryzumvi is a preservation-free eye drop formulation of phentolamine mesylate, an alpha adrenergic blocker. The Food and Drug Administration (FDA) has approved Ryzumvi™ ...

Dublin, Dec. 30, 2020 (GLOBE NEWSWIRE) -- The "Mydriasis - Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. The 'Mydriasis ...

Please provide your email address to receive an email when new articles are posted on . Nyxol, an alpha 1/2 antagonist eye drop, helped reverse the effects of pharmacologically induced mydriasis in ...

Credit: Getty Images. MydCombi is a combination of tropicamide, an anticholinergic, and phenylephrine hydrochloride, an alpha-1 adrenergic receptor agonist. The Food and Drug Administration (FDA) has ...

The FDA has approved phentolamine ophthalmic solution (Ryzumvi) 0.75% for treatment-induced mydriasis, Viatris and Ocuphire Pharma announced. The approval stipulates use of the eye drops to manage ...

FARMINGTON HILLS, Mich., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small ...

Eyenovia, Inc.EYEN announced that it has initiated enrollment of patients in a phase III study - MIST-1 - to evaluate MicroStat as a treatment for pharmacologic mydriasis (dilation of the pupil). The ...